Severity
Moderate
FDA Drug recall · Reported January 31, 2024
Lack of Sterility Assurance: Aseptic process simulation failure.
Be Pharmaceuticals Ag recalled Fosaprepitant for Injection 150 mg per vial, Sterile lyophilized powder for Intravenous u… - a moderate-severity action.
Fosaprepitant for Injection 150 mg per vial, Sterile lyophilized powder for Intravenous u… was recalled by Be Pharmaceuticals Ag in January 31, 2024. Reason: Lack of Sterility Assurance: Aseptic process simulation failure.. Check the official notice for the remedy. Verify recall #D-0262-2024 with the FDA Drug before acting.
The recall
Be Pharmaceuticals Ag issued this moderate-severity FDA Drug recall-Lack of Sterility Assurance: Aseptic process simulation failure..
Sourced from official FDA Drug enforcement records. Verify recall #D-0262-2024 with the agency before acting. Full product description, hazard, remedy, and related recalls are below.
This FDA Drug action (record #D-0262-2024) was formally reported on January 31, 2024, with the manufacturer initiating the action on January 10, 2024. It is classified under Moderate severity (Class II), with a current status of Terminated. Be Pharmaceuticals Ag is listed as the recalling firm, operating out of Zug, N/A. Federal records list the affected scope as 22,176 Vials.
The documented reason for this recall is: Lack of Sterility Assurance: Aseptic process simulation failure. Distribution data in the federal record shows the product reached: Nationwide in the USA. Distribution scope directly affects the consumer exposure window and determines whether a recall remains regional or escalates into a nationwide advisory.
Within the same product category the archive holds 6 closely related recalls, 5 from FDA Drug - clustering in a narrow category often points to a systemic quality-control or supplier issue rather than a one-off defect. Always verify the recall number against the official agency record before acting.
Where this recall sits in its category - 14,287 drugs & medications recalls on record
Of 101,704 recalls in the database, 24,878 are high severity, 72,426 moderate, and 4,400 low. This recall is classified moderate severity.
Counts reflect market size and reporting activity, not inherent danger, we do not rank products by risk from raw recall volume.
Severity
Moderate
Affected scope
22,176 Vials
Related Recalls
6
5 from same agency
Fosaprepitant for Injection 150 mg per vial, Sterile lyophilized powder for Intravenous use only after reconstitution and dilution, Single Dose Vial, Rx Only, Distributed by BE Pharmaceuticals Inc. 203 New Edition Court Cary, NC 27511, Made in India, NDC 71839-104-01.
Lack of Sterility Assurance: Aseptic process simulation failure.
| Attribute | Value |
|---|---|
| Agency | U.S. Food and Drug Administration |
| Severity class | Moderate (Class II) |
| Status | Terminated |
| Recall number | D-0262-2024 |
| Date reported | January 31, 2024 |
| Date initiated | January 10, 2024 |
| Recalling firm | Be Pharmaceuticals Ag |
| Firm location | Zug, N/A |
| Affected scope | 22,176 Vials |
| Distribution | Nationwide in the USA |
Profile values are sourced directly from the official FDA Drug enforcement record. Source: U.S. Food and Drug Administration.
What to do with this recall
Match your product against the recall record, then act on the agency remedy.
This page summarizes the official FDA Drug record for research and awareness; it is not legal, medical, or safety advice. Verify with the issuing agency before acting.
Other recalls in the same product category, useful for spotting patterns across the same defect class or manufacturer.
AbbVie Inc. · 2026-06-03
Llorens Pharmaceuticals International Division, Inc. · 2026-05-27
Safecor Health, LLC · 2026-05-27
IntegraDose Compounding Services LLC · 2026-05-27
Lupin Pharmaceuticals Inc. · 2026-05-27
Compare this recall with PRED MILD, prednisolone acetate ophthalmic suspension, USP,… →
Every figure on PlainRecalls is rendered directly from official FDA, CPSC and NHTSA recall records, no number is typed in by an editor. This recall: FDA Drug, reported January 31, 2024. Severity classes follow each agency's own taxonomy (FDA Class I/II/III; CPSC and NHTSA by hazard type), and related-recall context is computed across the full archive. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of July 2026.